Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30785815 | 1.00 | KDM4E (0.55) | KDM4ETSHRALDH1A1HPGDHTT | |
| SCHEMBL6890668 | 0.90 | TSHR (0.53) | KDM4ETSHRALDH1A1HPGDHTT | |
| SCHEMBL6888220 | 0.90 | TSHR (0.53) | KDM4ETSHRALDH1A1HPGDHTT | |
| SCHEMBL30468344 | 0.88 | KDM4E (0.47) | KDM4ETSHRALDH1A1HPGDHTT | |
| SCHEMBL12775293 | 0.86 | TSHR (0.56) | TSHRALDH1A1HPGDHTTHSD17B10 | |
| SCHEMBL6890524 | 0.85 | TSHR (0.54) | TSHRALDH1A1HTTHSD17B10L3MBTL1 | |
| SCHEMBL3583783 | 0.83 | MAPT (0.47) | KDM4ETSHRALDH1A1HPGDHTT | |
| SCHEMBL844529 | 0.83 | KDM4E (0.51) | KDM4ETSHRALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL16857456 | 0.81 | KDM4E (0.53) | KDM4ETSHRALDH1A1HPGDHTT | |
| SCHEMBL12752482 | 0.80 | TSHR (0.49) | TSHRALDH1A1HTTHSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719394-A2 | INHIBITORS OF TYK2 | Atomwise Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260048051-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | ATOMWISE INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12358904-B2 | Inhibitors of TYK2 | Atomwise Inc. (US) | 2025-07-15 | — | — | US | disclosed |
| US-20240417396-A1 | INHIBITORS OF TYK2 | Atomwise Inc. | 2024-12-19 | — | — | US | disclosed |
| WO-2024250010-A2 | INHIBITORS OF TYK2 | Atomwise Inc. (US) | 2024-12-05 | — | — | WO | disclosed |
| CN-117642385-A | Pesticidally active cyclic amine compounds | 先正达农作物保护股份公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20240002341-A1 | METHODS OF MAKING NICOTINIC ACID DERIVATIVES | AURORIUM HOLDINGS LLC | 2024-01-04 | — | — | US | disclosed |
| EP-4232028-A1 | METHODS OF MAKING NICOTINIC ACID DERIVATIVES | Vertellus Holdings LLC (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-116635369-A | Process for preparing nicotinic acid derivatives | 弗特鲁斯控股有限责任公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-111566103-B | Aminoimidazopyrazines as kinase inhibitors | 百时美施贵宝公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2015187934-A1 | FUNCTIONALIZED HETROARYL ENONES EXHIBITING NRF2 ACTIVATION AND THEIR METHOD OF USE | CUREVEDA, LLC (US) | 2015-12-10 | — | — | WO | disclosed |
| CN-102977009-A | Synthesizing method of 2-trifluoromethyl-3-fluoropyridin | HANGZHOU ALLSINO CHEMICAL CO LTD | 2013-03-20 | — | — | CN | disclosed |
| CN-101965334-A | Novel precursors | BIAL PORTELA & CA SA | 2011-02-02 | — | — | CN | disclosed |
| US-20100292482-A1 | NOVEL PRECURSORS | BIAL -Portela & CA.., S.A. | 2010-11-18 | — | — | US | disclosed |
| EP-2217571-A2 | NOVEL PRECURSORS | BIAL - Portela & Ca., S.A. (PT) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009054742-A2 | NOVEL PRECURSORS | BIAL - PORTELA & CA., S.A. (PT) | 2009-04-30 | — | — | WO | disclosed |
| US-6777556-B2 | REACTING KETO-VINYL ETHER COMPOUND WITH DIALKYLAMINOACRYLATE COMPOUND TO OBTAIN DIALKYLAMINO-OXO-ESTER COMPOUND; REACTING WITH AMMONIA OR AMMONIUM COMPOUND TO FORM NICOTINIC ESTER COMPOUND, HYDROLYSIS | BAYER CHEMICALS AG (DE) | 2004-08-17 | — | — | US | disclosed |
| US-20030176468-A1 | Process for preparing 2-haloalkylnicotinic acids | LANXESS DEUTSCHLAND GMBH (DE) | 2003-09-18 | — | — | US | disclosed |
| EP-1340747-A1 | Process for the preparation of 2-halogene-alkyl nicotinic acid alkyl-esters | BAYER AG (DE) | 2003-09-03 | — | — | EP | disclosed |
| CN-1053428-A | Substituted pyridine compound | MONSANTO CO (US) | 1991-07-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240417396-A1 | INHIBITORS OF TYK2 | TYK2, LCK, JAK2 | KDM4E 302/4885TSHR 1383/4885ALDH1A1 4785/4885 |
| US-20260048051-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | TYK2, FRK, DYRK2 | KDM4E 642/4885TSHR 445/4885ALDH1A1 4552/4885 |
| US-20100292482-A1 | NOVEL PRECURSORS | CBR3, CBR1, C1R | KDM4E 1533/4885TSHR 644/4885ALDH1A1 1363/4885 |
| US-20030176468-A1 | Process for preparing 2-haloalkylnicotinic acids | HDHD5, GNPAT, HACL2 | KDM4E 3641/4885TSHR 3401/4885ALDH1A1 252/4885 |
| US-12358904-B2 | Inhibitors of TYK2 | TYK2, LCK, JAK2 | KDM4E 302/4885TSHR 1383/4885ALDH1A1 4785/4885 |
| US-20240002341-A1 | METHODS OF MAKING NICOTINIC ACID DERIVATIVES | NAPRT, NNMT, NAMPT | KDM4E 2875/4885TSHR 3251/4885ALDH1A1 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.